Your browser doesn't support javascript.
loading
Mechanisms of Vascular Inflammation and Potential Therapeutic Targets: A Position Paper From the ESH Working Group on Small Arteries.
Rios, Francisco J; de Ciuceis, Carolina; Georgiopoulos, Georgios; Lazaridis, Antonios; Nosalski, Ryszard; Pavlidis, George; Tual-Chalot, Simon; Agabiti-Rosei, Claudia; Camargo, Livia L; Dabrowska, Edyta; Quarti-Trevano, Fosca; Hellmann, Marcin; Masi, Stefano; Lopreiato, Mariarosaria; Mavraganis, Georgios; Mengozzi, Alessandro; Montezano, Augusto C; Stavropoulos, Konstantinos; Winklewski, Pawel J; Wolf, Jacek; Costantino, Sarah; Doumas, Michael; Gkaliagkousi, Eugenia; Grassi, Guido; Guzik, Tomasz J; Ikonomidis, Ignatios; Narkiewicz, Krzysztof; Paneni, Francesco; Rizzoni, Damiano; Stamatelopoulos, Kimon; Stellos, Konstantinos; Taddei, Stefano; Touyz, Rhian M; Virdis, Agostino.
Afiliação
  • Rios FJ; Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada (F.J.R., L.L.C., A.C.M., R.M.T.).
  • de Ciuceis C; Department of Clinical and Experimental Sciences, University of Brescia (C.d.C., C.A.-R., D.R.).
  • Georgiopoulos G; Angiology and Endothelial Pathophysiology Unit, Department of Clinical Therapeutics, Medical School (G.G., G.M., K. Stamatelopoulos), National and Kapodistrian University of Athens.
  • Lazaridis A; Third Department of Internal Medicine, Aristotle University of Thessaloniki, Papageorgiou Hospital, Greece (A.L., E.G.).
  • Nosalski R; Centre for Cardiovascular Sciences; Queen's Medical Research Institute, University of Edinburgh, United Kingdom (R.N., T.J.G.).
  • Pavlidis G; Department of Internal Medicine, Center for Medical Genomics OMICRON, Jagiellonian University Medical College, Krakow, Poland (R.N., T.J.G.).
  • Tual-Chalot S; Medical School (G.P., I.I.), National and Kapodistrian University of Athens.
  • Agabiti-Rosei C; Preventive Cardiology Laboratory and Clinic of Cardiometabolic Diseases, 2-Cardiology Department, Attikon Hospital, Athens, Greece (G.P., I.I.).
  • Camargo LL; Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, United Kingdom (S.T.-C., K. Stellos).
  • Dabrowska E; Department of Clinical and Experimental Sciences, University of Brescia (C.d.C., C.A.-R., D.R.).
  • Quarti-Trevano F; Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada (F.J.R., L.L.C., A.C.M., R.M.T.).
  • Hellmann M; Department of Hypertension and Diabetology, Center of Translational Medicine (E.D., J.W., K.N.) and M.D.).
  • Masi S; Clinica Medica, Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy (F.Q.-T., G.G.).
  • Lopreiato M; Cardiac Diagnostics (M.H.), Medical University of Gdansk, Poland.
  • Mavraganis G; Institute of Cardiovascular Science, University College London, United Kingdom (S.M.).
  • Mengozzi A; Department of Clinical and Experimental Medicine, University of Pisa, Italy (S.M., M.L., A.M., S.T., A.V.).
  • Montezano AC; Department of Clinical and Experimental Medicine, University of Pisa, Italy (S.M., M.L., A.M., S.T., A.V.).
  • Stavropoulos K; Angiology and Endothelial Pathophysiology Unit, Department of Clinical Therapeutics, Medical School (G.G., G.M., K. Stamatelopoulos), National and Kapodistrian University of Athens.
  • Winklewski PJ; Department of Clinical and Experimental Medicine, University of Pisa, Italy (S.M., M.L., A.M., S.T., A.V.).
  • Wolf J; Center for Translational and Experimental Cardiology, Department of Cardiology, University Hospital Zurich, University of Zurich, Switzerland (A.M., F.P.).
  • Costantino S; Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa (A.M.).
  • Doumas M; Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada (F.J.R., L.L.C., A.C.M., R.M.T.).
  • Gkaliagkousi E; Second Medical Department, Hippokration Hospital, Aristotle University of Thessaloniki, Greece (K. Stavropoulos).
  • Grassi G; Departments of Human Physiology (P.J.W.), Medical University of Gdansk, Poland.
  • Guzik TJ; Department of Hypertension and Diabetology, Center of Translational Medicine (E.D., J.W., K.N.) and M.D.).
  • Ikonomidis I; University Heart Center (S.C., F.P.), University Hospital Zurich, Switzerland.
  • Narkiewicz K; Department of Hypertension and Diabetology, Center of Translational Medicine (E.D., J.W., K.N.) and M.D.).
  • Paneni F; Third Department of Internal Medicine, Aristotle University of Thessaloniki, Papageorgiou Hospital, Greece (A.L., E.G.).
  • Rizzoni D; Clinica Medica, Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy (F.Q.-T., G.G.).
  • Stamatelopoulos K; Centre for Cardiovascular Sciences; Queen's Medical Research Institute, University of Edinburgh, United Kingdom (R.N., T.J.G.).
  • Stellos K; Department of Internal Medicine, Center for Medical Genomics OMICRON, Jagiellonian University Medical College, Krakow, Poland (R.N., T.J.G.).
  • Taddei S; Medical School (G.P., I.I.), National and Kapodistrian University of Athens.
  • Touyz RM; Preventive Cardiology Laboratory and Clinic of Cardiometabolic Diseases, 2-Cardiology Department, Attikon Hospital, Athens, Greece (G.P., I.I.).
  • Virdis A; Department of Hypertension and Diabetology, Center of Translational Medicine (E.D., J.W., K.N.) and M.D.).
Hypertension ; 81(6): 1218-1232, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38511317
ABSTRACT
Inflammatory responses in small vessels play an important role in the development of cardiovascular diseases, including hypertension, stroke, and small vessel disease. This involves various complex molecular processes including oxidative stress, inflammasome activation, immune-mediated responses, and protein misfolding, which together contribute to microvascular damage. In addition, epigenetic factors, including DNA methylation, histone modifications, and microRNAs influence vascular inflammation and injury. These phenomena may be acquired during the aging process or due to environmental factors. Activation of proinflammatory signaling pathways and molecular events induce low-grade and chronic inflammation with consequent cardiovascular damage. Identifying mechanism-specific targets might provide opportunities in the development of novel therapeutic approaches. Monoclonal antibodies targeting inflammatory cytokines and epigenetic drugs, show promise in reducing microvascular inflammation and associated cardiovascular diseases. In this article, we provide a comprehensive discussion of the complex mechanisms underlying microvascular inflammation and offer insights into innovative therapeutic strategies that may ameliorate vascular injury in cardiovascular disease.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inflamação Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inflamação Idioma: En Ano de publicação: 2024 Tipo de documento: Article